Clinical Trial Update: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of A3907 in adults with Primary Sclerosing Cholangitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• A3907

Snippet

Sponsor: Albireo, an Ipsen Company | Conditions: Primary Sclerosing Cholangitis | Phase 2 | Status: COMPLETED